ERBB2 and breast carcinoma: Approximately 71% of patients with breast cancer have hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐not‐amplified (HER2‐negative) disease, which is associated with a favorable short‐term prognosis.3